Novo Nordisk has agreed to transfer rights of an experimental Parkinson’s therapy to Cellular Intelligence, a Mark Zuckerberg-backed AI startup, in a deal that includes milestone payments, royalties and a stake in the Boston-based firm.
Novo Nordisk has handed over an experimental Parkinson’s disease therapy to Cellular Intelligence, a Mark Zuckerberg-backed AI startup, in a bid to accelerate its development, according to Bloomberg.
The Boston-based startup will take charge of shepherding the early-stage treatment through clinical trials. In return, Novo — maker of obesity blockbuster Wegovy — stands to receive milestone payments and royalties if the programme succeeds.
As part of the agreement, the Danish drugmaker will also acquire a stake in Cellular Intelligence. No financial details were disclosed.
The deal signals a growing trend of major pharmaceutical companies partnering with AI-driven startups to speed up drug development, particularly for complex neurological conditions such as Parkinson’s disease.
NEWS NOW:
- Obama on Iran: “We pulled it off without firing a missile. We got 97% of their enriched uranium out…
- Identity of France’s Third-Choice Goalkeeper for World Cup in Doubt; Lens’ Robin Risser Could Be Called Up
- Vice-president vows internal pressure at Grêmio to turn things around
- Everton should have got penalty for Fernandes handball – Webb
